These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19089768)

  • 21. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials.
    Thangaratinam S; Coomarasamy A
    Obstet Gynecol; 2005 Jun; 105(6):1483-4; author reply 1484. PubMed ID: 15932848
    [No Abstract]   [Full Text] [Related]  

  • 22. Attitudes and practices regarding use of progesterone to prevent preterm births.
    Henderson ZT; Power ML; Berghella V; Lackritz EM; Schulkin J
    Am J Perinatol; 2009 Aug; 26(7):529-36. PubMed ID: 19301227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progesterone for prevention of premature birth.
    Med Lett Drugs Ther; 2011 May; 53(1364):37-8. PubMed ID: 21566542
    [No Abstract]   [Full Text] [Related]  

  • 24. 17 Progesterone for preterm birth prevention: a potential 2 billion dollar opportunity.
    Armstrong J
    Am J Obstet Gynecol; 2007 Mar; 196(3):194-5. PubMed ID: 17346520
    [No Abstract]   [Full Text] [Related]  

  • 25. ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.
    Society for Maternal Fetal Medicine Publications Committee
    Obstet Gynecol; 2008 Oct; 112(4):963-5. PubMed ID: 18827143
    [No Abstract]   [Full Text] [Related]  

  • 26. Unintended consequences--the cost of preventing preterm births after FDA approval of a branded version of 17OHP.
    Armstrong J
    N Engl J Med; 2011 May; 364(18):1689-91. PubMed ID: 21410391
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of localized periodontal disease in pregnancy does not reduce the occurrence of preterm birth: results from the Periodontal Infections and Prematurity Study (PIPS).
    Boggess KA
    Am J Obstet Gynecol; 2010 Feb; 202(2):101-2. PubMed ID: 20113688
    [No Abstract]   [Full Text] [Related]  

  • 28. [Are gestagens suitable for lowering the membrane potential of the uterine muscle and eliminating the need for beta-mimetics?].
    Spätling L
    Gynakologe; 1992 Jun; 25(3):201. PubMed ID: 1354628
    [No Abstract]   [Full Text] [Related]  

  • 29. [Incidence of side effects of synthetic progestins with different content of estrogenic and gestagenic components].
    Rotkina IE; Lutsik LA; Dubovik NT
    Akush Ginekol (Mosk); 1977 Sep; (9):29-31. PubMed ID: 596558
    [No Abstract]   [Full Text] [Related]  

  • 30. Progestogen administration in pregnancy may prevent preterm delivery.
    Keirse MJ
    Br J Obstet Gynaecol; 1990 Feb; 97(2):149-54. PubMed ID: 2138496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of Preterm Labor with 17α-Hydroxyprogesterone (17OHP) Caproate: A Comparison of Adverse Drug Reaction Rates between Compounded and Commercial Formulations.
    Stone RH; Bobowski C; Milikhiker N; Anguiano RH; Mastrogiannis D
    Am J Perinatol; 2017 Dec; 34(14):1436-1441. PubMed ID: 28704849
    [No Abstract]   [Full Text] [Related]  

  • 32. Progesterone and preterm delivery--deja vu all over again.
    Greene MF
    N Engl J Med; 2003 Jun; 348(24):2453-5. PubMed ID: 12802032
    [No Abstract]   [Full Text] [Related]  

  • 33. The choice of progestogen for the prevention of preterm birth in women with singleton pregnancy and prior preterm birth.
    Society for Maternal-Fetal Medicine (SMFM) Publications Committee
    Am J Obstet Gynecol; 2017 Mar; 216(3):B11-B13. PubMed ID: 28126367
    [No Abstract]   [Full Text] [Related]  

  • 34. Prematurity in twin pregnancies.
    Bornstein E; Proudfit CL; Keeler SM
    Minerva Ginecol; 2009 Apr; 61(2):113-26. PubMed ID: 19255559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preterm birth: advances in prevention management.
    Simpson N
    Semin Fetal Neonatal Med; 2004 Dec; 9(6):427. PubMed ID: 15691779
    [No Abstract]   [Full Text] [Related]  

  • 36. Gestiva for preventing prematurity: a new view of an old therapy.
    Cypher R
    Nurs Womens Health; 2007 Jun; 11(3):322-5. PubMed ID: 17883780
    [No Abstract]   [Full Text] [Related]  

  • 37. Medical cost savings associated with 17 alpha-hydroxyprogesterone caproate.
    Bailit JL; Votruba ME
    Am J Obstet Gynecol; 2007 Mar; 196(3):219.e1-7. PubMed ID: 17346527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are oral betamimetics effective maintenance therapies after threatened preterm labor?
    Griffin G
    Am Fam Physician; 2007 Mar; 75(5):648-9. PubMed ID: 17375508
    [No Abstract]   [Full Text] [Related]  

  • 39. Are we stopping preterm birth trials too early?
    Byrne R; Mol B
    Am J Obstet Gynecol; 2016 Jan; 214(1):134-5. PubMed ID: 26363485
    [No Abstract]   [Full Text] [Related]  

  • 40. 17 Alpha-hydroxyprogesterone caproate for preterm prevention: issues in subgroup analysis.
    Klebanoff MA
    Am J Obstet Gynecol; 2016 Mar; 214(3):306-7. PubMed ID: 26928145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.